Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.

Abstract:

BACKGROUND:Prostaglandin analogues are effective ocular hypotensive agents and are being used increasingly in the treatment of elevated intraocular pressure (IOP). These agents are typically dosed once daily. OBJECTIVES:A pilot study was conducted to evaluate the duration of travoprost's IOP-lowering efficacy up to 84 hours after the final dose in patients with open-angle glaucoma. A follow-up study was conducted to compare diurnal IOP control with travoprost and latanoprost over a 44-hour period. METHODS:In the open label pilot study, patients received 0.004% travoprost in both eyes at 8 pm daily for 2 weeks. After 2 weeks, IOP was measured before administration of the last daily dose, every 4 hours thereafter for 36 hours, and 60 and 84 hours after the last dose, with no additional ocular hypotensive medication given. In the controlled, double-masked, parallel-group, follow-up study, patients were randomized to self-administer 1 drop of the marketed doses of 0.004% travoprost or 0.005% latanoprost in both eyes at 8 pm daily for 2 weeks. At the end of this period, patients returned to the facility at approximately 8 pm for IOP measurement and administration of the final dose of study medication. IOP was then measured at 4-hour intervals for 44 hours after the last dose, with no additional ocular hypotensive medication given. RESULTS:The pilot study included 21 patients (67% female, 33% male; age range, 35-81 years) with open-angle glaucoma. IOP values were significantly below baseline at all time points up to 84 hours after the final dose of travoprost ( P<0.001). The follow-up study enrolled 35 patients, 1 of whom was excluded for missing data; thus, the intent-to-treat analysis included 34 patients (68% female, 32% male; age range, 36-72 years). At the unmedicated eligibility visit, mean IOP over 24 hours ranged from 21 to 26 mm Hg in each treatment group. After 2 weeks of treatment and 24 hours after the last dose, mean (SD) IOP was 13.1 (2.1) mm Hg (change from eligibility visit, -10.4 [2.7] mm Hg) in the travoprost group and 16.0 (3.1) mm Hg (change from eligibility visit, -7.1 [2.4] mm Hg) in the latanoprost group. The difference in change from baseline was statistically significant between treatment groups (P=0.006). Travoprost lowered IOP significantly at all time points throughout the 44-hour period after the last dose (mean IOP,

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Dubiner HB,Sircy MD,Landry T,Bergamini MV,Silver LH,Darell Turner F,Robertson S,Andrew RM,Weiner A,Przydryga J

doi

10.1016/s0149-2918(04)90008-2

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

84-91

issue

1

eissn

0149-2918

issn

1879-114X

pii

S0149291804900082

journal_volume

26

pub_type

临床试验,杂志文章,随机对照试验
  • Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.

    abstract:BACKGROUND:Concomitant aspirin use is a risk factor for nonsteroidal anti-inflammatory drug (NSAID)-associated upper gastrointestinal toxicity. In high-risk individuals, such as those with a history of NSAID-related gastric ulcer bleeding, gastroprotective therapy with a proton pump inhibitor has been reported to reduc...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2004.10.002

    authors: Goldstein JL,Huang B,Amer F,Christopoulos NG

    更新日期:2004-10-01 00:00:00

  • Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.

    abstract:PURPOSE:Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2017.06.014

    authors: Sohn IS,Kim CJ,Ahn T,Youn HJ,Jeon HK,Ihm SH,Cho EJ,Chung WB,Chae SC,Kim WS,Nam CW,Park SM,Choi JY,Kim YK,Hong TJ,Lee HY,Cho JH,Shin ES,Yoon JH,Yang TH,Jeong MH,Lee JH,Park JI

    更新日期:2017-08-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.

    abstract:BACKGROUND:Impaired mineral homeostasis affecting calcium, phosphate, and magnesium is a result of parathyroid hormone (PTH) deficiency in hypoparathyroidism. The current standard of treatment with active vitamin D and oral calcium does not control levels of these major minerals. Recombinant full-length human PTH 1-84 ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.04.001

    authors: Clarke BL,Kay Berg J,Fox J,Cyran JA,Lagast H

    更新日期:2014-05-01 00:00:00

  • Comparison of Escherichia coli susceptibility to cephalothin, cefazolin, ceforanide, and cefamandole.

    abstract::Twenty-seven Escherichia coli test strains that were not susceptible to cephalothin were tested for susceptibility to cefazolin, cefamandole, and ceforanide. By zone-size criteria (greater than or equal to 18 mm), 67% of E coli were susceptible to cefazolin and cefamandole, and 93% were susceptible to ceforanide. By m...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Greenberg RN,Bollinger M

    更新日期:1985-01-01 00:00:00

  • Variation in Plasma Levels of Glucosamine With Chronic Dosing: A Possible Reason for Inconsistent Clinical Outcomes in Osteoarthritis.

    abstract:PURPOSE:Glucosamine is widely used by patients with osteoarthritis (OA) to provide symptomatic relief and to delay disease progression. However, clinical studies have reported inconsistent clinical outcomes. The current study hypothesized that the reported inconsistent clinical results could be, in part, due to variabl...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clinthera.2020.06.009

    authors: Asthana C,Peterson GM,Shastri MD,Jones G,Patel RP

    更新日期:2020-08-01 00:00:00

  • Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.

    abstract:BACKGROUND:Prophylaxis with granulocyte colony-stimulating factor reduces the risk for febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy. OBJECTIVE:We estimated the incremental cost-effectiveness of primary prophylaxis (starting in cycle 1 of chemotherapy) with pegfilgrastim versus filgrasti...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2009.05.003

    authors: Lyman GH,Lalla A,Barron RL,Dubois RW

    更新日期:2009-05-01 00:00:00

  • Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.

    abstract:BACKGROUND:Biosimilars are defined as biologic products that are highly similar to reference products, notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences between the biologic product and the reference product in terms of safety profile, purity, and potency. Du...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2011.12.005

    authors: Ahmed I,Kaspar B,Sharma U

    更新日期:2012-02-01 00:00:00

  • Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers.

    abstract:BACKGROUND:It has been reported that the efficacy of acute forms of nicotine replacement therapy, such as nicotine gum and lozenges, improves when sufficient quantities of medication are used. OBJECTIVE:This analysis examined whether adherence with daily nicotine patch wear was associated with improved rates of smokin...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2008.09.016

    authors: Shiffman S,Sweeney CT,Ferguson SG,Sembower MA,Gitchell JG

    更新日期:2008-10-01 00:00:00

  • Ambrisentan for the management of pulmonary arterial hypertension.

    abstract:BACKGROUND:Approved by the US Food and Drug Administration in 2007, ambrisentan is the second oral endothelin A-receptor antagonist available for the management of pulmonary arterial hypertension (PAH) in patients with World Health Organization class II or III symptoms. OBJECTIVE:This article examines the clinical pha...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2008.05.005

    authors: Cheng JW

    更新日期:2008-05-01 00:00:00

  • Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-control

    abstract:PURPOSE:Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously. Traditionally, treatment of these multiple conditions required separate medications for each disease, which may result in poor compliance and thus lead to possible treatment failure. Fixed-dose combinat...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2018.03.010

    authors: Oh GC,Han JK,Han KH,Hyon MS,Doh JH,Kim MH,Jeong JO,Bae JH,Kim SH,Yoo BS,Baek SH,Rhee MY,Ihm SH,Sung JH,Choi YJ,Kim SJ,Hong KS,Lee BK,Cho J,Shin ES,Rhew JY,Kim H,Kim HS

    更新日期:2018-05-01 00:00:00

  • Review of the therapeutic uses of liraglutide.

    abstract:BACKGROUND:Glucagon-like peptide (GLP-1) is a neuroendocrine hormone that increases blood glucose and is a drug target for treatment of type 2 diabetes. Liraglutide, a subcutaneous, once-daily GLP-1 agonist, is approved for the treatment of type 2 diabetes in the United States and Europe. It also has been studied for w...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2011.06.004

    authors: Ryan GJ,Foster KT,Jobe LJ

    更新日期:2011-07-01 00:00:00

  • Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

    abstract:BACKGROUND:Many patients with type 2 diabetes mellitus (T2DM) also have hypertension, which is commonly treated with thiazide diuretics, including hydrochlorothiazide (HCTZ). Canagliflozin, a sodium glucose cotransporter 2 inhibitor developed for the treatment of T2DM, lowers plasma glucose by inhibiting renal glucose ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.02.022

    authors: Devineni D,Vaccaro N,Polidori D,Rusch S,Wajs E

    更新日期:2014-05-01 00:00:00

  • Insulin glargine.

    abstract:BACKGROUND:In diabetes mellitus, the clinical goal of intensive glycemic control (lowering blood glucose concentrations to normal or near-normal levels) has been hindered by the lack of insulin regimens that duplicate the basal-bolus secretion of insulin by the healthy pancreas. In particular, intensive therapy has bee...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(01)80148-x

    authors: Campbell RK,White JR,Levien T,Baker D

    更新日期:2001-12-01 00:00:00

  • Effect of citalopram on plasma levels of oral theophylline.

    abstract:BACKGROUND:Citalopram and theophylline may be prescribed together to treat patients with depression and asthmatic disease. Because theophylline has a low therapeutic index, small changes in plasma levels may result in therapeutic failure or adverse effects. Both citalopram and theophylline are metabolized by cytochrome...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0149-2918(00)83047-7

    authors: Møller SE,Larsen F,Pitsiu M,Rolan PE

    更新日期:2000-12-01 00:00:00

  • Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?

    abstract:PURPOSE:Although recent reports suggest an association between saxagliptin and an increased risk of admissions for heart failure, it is not clear whether dipeptidyl peptidase IV (DPP-IV) inhibition contributes to heart failure in high-risk patients. The purpose of this research is to understand heart failure risk among...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2014.10.009

    authors: Clifton P

    更新日期:2014-12-01 00:00:00

  • A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer.

    abstract::A phase II study of weekly low-dose doxorubicin (6 to 12 mg/m2) showed it to be an effective, well-tolerated therapy in advanced breast cancer. Although most of the 34 patients studied had been clinically resistant to previous endocrine measures and/or other kinds of chemotherapy, had a median score of 60 on Karnofsky...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Mattsson W,Borgström S,Landberg T

    更新日期:1982-01-01 00:00:00

  • Inhaled dry powder insulin for the treatment of diabetes mellitus.

    abstract:BACKGROUND:Inhaled dry powder insulin (IDPI) is the first inhaled insulin approved for the treatment of type 1 and type 2 diabetes mellitus (DM). OBJECTIVE:This article reviews available information on IDPI, focusing on its clinical pharmacokinetics, comparative efficacy, tolerability, adverse events, dosage and admin...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.05.015

    authors: Setter SM,Levien TL,Iltz JL,Odegard PS,Neumiller JJ,Baker DE,Campbell RK

    更新日期:2007-05-01 00:00:00

  • Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension.

    abstract::A drug surveillance study was performed to determine the tolerance and safety of quinapril in the treatment of patients with stage 1 or 2 hypertension. The trial was noncomparative, open-label, uncontrolled, and nonrandomized. Patients with secondary hypertension, heart failure, other heart diseases, and other serious...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0149-2918(96)80046-4

    authors: Olvera S,Alcocer L,Novoa G

    更新日期:1996-09-01 00:00:00

  • Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.

    abstract:BACKGROUND:The real-world clinical effectiveness of exogenous insulin is limited by nonadherence. Various insulin delivery systems have been developed to help improve adherence, with prefilled pens gaining popularity among adult Singaporeans with diabetes. However, adherence to insulin in people with diabetes in Singap...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.05.009

    authors: Cheen HH,Lim SH,Huang MC,Bee YM,Wee HL

    更新日期:2014-07-01 00:00:00

  • Amino acids for dialysis patients.

    abstract::Calorie/protein malnutrition is a common problem among dialysis patients. A study was designed to determine the value of adding a mixture of amino acids to the diet of 36 patients (mean age, 42 years) who had been receiving triweekly hemodialysis for periods ranging from 1 to 13 years. For 1 month the patients receive...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Mastroiacovo P,Pace V,Sagliaschi G

    更新日期:1993-07-01 00:00:00

  • Tolerability and efficacy of long-term daily administration of indomethacin for moderate to severe chronic arthritic disorders.

    abstract::The long-term tolerability and efficacy of indomethacin were evaluated in a retrospective study of 67 patients with moderate to severe rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis who took the drug daily for periods ranging from three to 20 years. Only patients who had not experienced side effects d...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Lockie LM

    更新日期:1986-01-01 00:00:00

  • Respiratory symptoms due to Branhamella catarrhalis and other Neisseria species infections--response to erythromycin therapy.

    abstract::Neisseria microorganisms (Neisseria lactamica, Neisseria sicca, and Neisseria mucosa) are regarded as normal respiratory commensals. Branhamella catarrhalis (formerly Neisseria catarrhalis) has also been regarded as a normal respiratory commensal, but reports indicate that it can be pathogenic. The role of Neisseria s...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Hamedani P,Hafiz S,Ali J,Memon R,Ali S,Ali M,Ansari M,Siddique I,Raza R

    更新日期:1989-09-01 00:00:00

  • Safety Alerts: An Observational Study in Portugal.

    abstract:PURPOSE:The information that is available when marketing authorizations are approved is limited. Pharmacovigilance has an important role during the postauthorization period, and alerts published by national authorities allow health care professionals to be informed about new data on safety profiles. This study therefor...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2015.07.015

    authors: Soares S,Roque F,Teixeira Rodrigues A,Figueiras A,Herdeiro MT

    更新日期:2015-09-01 00:00:00

  • Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.

    abstract:BACKGROUND:Alendronate, an oral bisphosphonate, is available for the treatment of osteoporosis in a 70-mg once-weekly and a 10-mg once-daily formulation. OBJECTIVES:This study aimed to determine patient preference for once-weekly versus once-daily dosing with alendronate, and to determine which treatment regimen the p...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/s0149-2918(02)80085-6

    authors: Simon JA,Lewiecki EM,Smith ME,Petruschke RA,Wang L,Palmisano JJ

    更新日期:2002-11-01 00:00:00

  • Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.

    abstract:BACKGROUND:Ezetimibe (EZE) is a cholesterol-lowering drug that inhibits absorption of dietary and biliary cholesterol across the intestinal wall without affecting absorption of bile acids, fatty acids, fat-soluble vitamins, or triglycerides. It has a complementary mechanism of action to the statins, which inhibit chole...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2005.02.011

    authors: Masana L,Mata P,Gagné C,Sirah W,Cho M,Johnson-Levonas AO,Meehan A,Troxell JK,Gumbiner B,Ezetimibe Study Group.

    更新日期:2005-02-01 00:00:00

  • Amoxicillin and clavulanic acid combination: clinical and laboratory evaluation in pulmonary infections.

    abstract::Twenty-four patients with pulmonary infections (7 pneumoniae, 17 exacerbations of chronic bronchitis) were treated with a combination of 250 mg of amoxicillin and 125 mg of clavulanic acid supplemented by 500 mg of amoxicillin every eight hours. All patients showed good clinical, roentgenological, and bacteriological ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Saroglou G,Paniara-Volika O,Sima A,Paraskevopoulou E,Makris G,Hatzimichelakis N,Vassilopoulos N,Kontomichalou P

    更新日期:1982-01-01 00:00:00

  • Comparative effectiveness of tiotropium and ipratropium in prevention of hospital readmission for COPD: a population-based cohort study.

    abstract:BACKGROUND:In the treatment of chronic obstructive pulmonary disease (COPD), tiotropium bromide has a longer duration of action than ipratropium bromide; however, tiotropium bromide is a more expensive alternative treatment. At issue is whether tiotropium reduces the risk for hospital readmissions for COPD compared wit...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2012.10.007

    authors: Kawasumi Y,Paterson MJ,Morrow RL,Miller TA,Bassett K,Wright JM,Dormuth CR

    更新日期:2013-04-01 00:00:00

  • Efficacy of budesonide in inhaled corticosteroid-naive patients and patients with mild persistent asthma.

    abstract:BACKGROUND:Patients with mild intermittent or mild persistent asthma represent 70% of asthma sufferers. Inhaled corticosteroids (ICSs) are the mainstay of treatment for persistent asthma, although many of the early clinical studies of these drugs included only patients with moderate to severe asthma. OBJECTIVE:This ar...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(02)80017-0

    authors: Eigen H

    更新日期:2002-07-01 00:00:00

  • Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.

    abstract:BACKGROUND:Optimal treatment regimens for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are not well-defined. OBJECTIVES:This study describes the treatment and outcomes in patients with urinary tract infection (UTI) caused by KPC-producing Enterobacteriaceae. METHODS:This...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2012.05.002

    authors: Alexander BT,Marschall J,Tibbetts RJ,Neuner EA,Dunne WM Jr,Ritchie DJ

    更新日期:2012-06-01 00:00:00

  • Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.

    abstract:PURPOSE:The comparative efficacy of endocrine-based therapies (ETs) for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) is not well characterized. This network meta-analysis (NMA) synthesized available evidence on progression-free survival (PFS) wit...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clinthera.2018.03.004

    authors: Ayyagari R,Tang D,Patterson-Lomba O,Zhou Z,Xie J,Chandiwana D,Dalal AA,Niravath PA

    更新日期:2018-04-01 00:00:00